biotech · Relapsed or Refractory Multiple Myeloma
Wuhan YZY Biopharma
Wuhan YZY Biopharma Co.,
Wuhan YZY Biopharma is a biotech organization headquartered in CN. Primary therapeutic focus areas include Relapsed or Refractory Multiple Myeloma. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 pat
Wuhan, CN HQ
2010 Founded
55 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Wuhan, CN
- Founded
- 2010
- Employees
- 55
- Programs
- 1
- Drugs
- 2
- Patents
- 0
Y150
Phase 1 · small molecule · Relapsed or Refractory Multiple Myeloma
Y150 for Relapsed or Refractory Multiple Myeloma is a Phase 1 program (small_molecule) at Wuhan YZY Biopharma Co., with 1 ClinicalTrials.gov record(s).
Internal code Y15001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Wuhan YZY Biopharma Co.,
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Relapsed or Refractory Multiple Myeloma
- Status
- completed
- Trials
- 1